2 weeks ago it set a new high at $49.09 and the next morning it was $4.50 lower, more or less.
It is a low float stock and subject to wild swings.
I just try to watch the trend..... which is good; increasingly upwards.
I feel as though (just as we saw recently with Gilead) that the strong hands are trying to shake out the little investors before an upswing.
Gilead has a great treatment and is a great program. It's crazy to sell at a low, IMHO. And yet many people did just that.
Today's ENTA share price drop means little to me in the actual value of the shares. The share price trend and the recent upgrade tells me to stay put.
The fundamentals of this stock have remained virtually unchanged in the year I have owned it; but the share price as been all over the place.
Yes, I agree that the upcoming approval indications will be important (12 week versus 24 week and for what indications)
This was a somewhat larger deal in the recent Gilead approvals;
8 week off label but left up to the doctor/viral load
24 weeks for one sub group.
When the Abbvie- ENTA 3D program is approved we will see some price swings in share price.
What will remain unknown, is the response by the payors.
For me, Gilead has a great program; it's fantastic!!!
But it is another question; what % of the sub-groups will get approval for treatments in the 3D program? The payment approval distribution will not the same as the HCV infected aggregate.
In my experience, I went untreated for 10 years with no issues; virtually no medical expense. The sick ones though..... they are 200x more expensive than the well ones.
IMHO, the sickest are going first, meaning that the sub-group where the 3-D program is strongest compared to Gilead/Harvoni TX.
This will be the largest unknown remaining when the Abbvie Program is approved, and pricing is listed.
I have little trading experience myself, and I sold at Gilead's Sovaldi approval. (either smart or lucky)
BUT....there is a potential for a buyout with this company, so it could pull an IDIX some morning when we wake up and look at share price. One could make some money selling at the news, to lose far more money while awaiting a lower buy in point.
At any given moment.... the value is not priced in, IMHO.
Recent ENTA News
- Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/30/2024 11:10:00 AM
- Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer • Business Wire • 04/30/2024 11:00:00 AM
- Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 • Business Wire • 04/29/2024 11:00:00 AM
- Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 • Business Wire • 04/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:27:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:15:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:12:41 PM
- Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference • Business Wire • 03/06/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:31:52 PM
- Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/27/2024 06:11:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:23:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:21:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:18:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:15:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:12:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:09:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:00:28 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:26:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:24:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:05:12 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET • Business Wire • 02/07/2024 09:01:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM